CureVac Says CV2CoV Showed High Immunogenicity Against Virus Variants In Preclinical Study

Biopharmaceutical company CureVac N.V. (CVAC) announced Thursday that its second generation COVID-19 vaccine candidate, CvnCoV, demonstrated high immunogenicity against virus variants in preclinical study. The first clinical trials for CV2CoV are expected to start in the third quarter of 2021.

CV2CoV is being developed in collaboration between Germany's CureVac and GlaxoSmithKline plc (GSK). This second generation vaccine candidate differs from CureVac's first-generation vaccine candidate, CVnCoV, currently in late-stage clinical testing.

The new CV2CoV vaccine candidate is based on a new mRNA backbone that features targeted optimizations designed to improve intracellular mRNA stability and translation for increased and extended protein expression.

CV2CoV showed high levels of antigen production in rat model. There was also a fast onset of strong neutralizing antibody titers after first vaccination and high cross-neutralizing capacity of induced antibodies against selected COVID-19 variants of concern, including the Denmark variant (B.1.1.298), the UK variant (B.1.1.7) and the South African variant (B.1.351).

CureVac and GlaxoSmithKline aim to jointly develop second-generation vaccine candidates that offer improved immune responses and target emerging variants. Combined with lower doses, these second-generation vaccines could enable also broad protection against selected strains in a multivalent vaccine format.

The COVID-19 collaboration between CureVac and GlaxoSmithKline announced in February 2021 extends the existing strategic mRNA technology partnership both companies entered in July 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mallinckrodt plc announced Wednesday that the U.S. Food and Drug Administration or FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for the treatment of adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Worldwide 5G mobile subscriptions are estimated to exceed 580 million by the end of 2021, according to the Ericsson Mobility Report. With subscriptions increasing at a rate of about a million per day, 5G remains on track to become the fastest adopted mobile generation in history. The growth in subscriptions is being lead by China, North America and the Gulf Cooperation Council markets. Elanco Animal Health Inc. (ELAN) and veterinary biopharmaceutical company Kindred Biosciences, Inc. (KIN) announced Wednesday they have entered into a definitive agreement for Elanco to acquire Kindred for $9.25 per share, or approximately $440 million. The acquisition further accelerates Elanco's...
Follow RTT